CriticalOxazolidinone antibiotic×Selective serotonin reuptake inhibitor (SSRI)
Updated · Methodology
Mechanism
Linezolid is an antibiotic that reversibly and non-selectively inhibits monoamine oxidase, so it is itself a monoamine oxidase inhibitor (MAOI). At antibacterial doses it has no antidepressant effect (linezolid summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Serotonin syndrome has been reported when linezolid was combined with serotonergic agents, including selective serotonin reuptake inhibitors (SSRIs) such as paroxetine (linezolid SmPC, AEMPS). This condition can be life-threatening (paroxetine label, US Food and Drug Administration, FDA). For this reason the FDA paroxetine label contraindicates paroxetine with MAOIs, linezolid included, and within 14 days of stopping them. The Spanish SmPCs of both drugs also contraindicate the combination but allow it in exceptional cases, if close observation for serotonin syndrome and blood pressure monitoring are possible (paroxetine and linezolid SmPCs, AEMPS). Linezolid is not detectably metabolised by cytochrome P450 enzymes and does not inhibit them, so no interactions are expected through this route (linezolid SmPC, AEMPS).
Symptoms
Serotonin syndrome causes mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, dizziness, sweating, flushing, fever), neuromuscular signs (tremor, rigidity, muscle jerks, hyperreflexia, incoordination), seizures, nausea, vomiting and diarrhoea (paroxetine label, US Food and Drug Administration, FDA). When the combination cannot be avoided, the Spanish linezolid summary of product characteristics (SmPC) names the signs to watch for: cognitive dysfunction, very high fever, hyperreflexia and incoordination. Symptoms may resolve once the serotonergic drug is stopped (linezolid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The condition can be life-threatening (paroxetine SmPC, AEMPS).
Management
The combination is contraindicated. Under the paroxetine label of the US Food and Drug Administration (FDA), paroxetine must not be taken with monoamine oxidase inhibitors (MAOIs), linezolid included, or within 14 days of stopping them (paroxetine label, FDA). Do not start paroxetine in a patient being treated with linezolid (paroxetine label, FDA). If a patient on paroxetine needs linezolid, stop paroxetine before the first linezolid dose (paroxetine label, FDA). The Spanish paroxetine summary of product characteristics (SmPC) asks for at least one week between stopping paroxetine and starting any MAOI (paroxetine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Under the Spanish SmPCs, the two drugs may be given together only in exceptional cases: when linezolid cannot be avoided and close observation for serotonin syndrome and blood pressure monitoring are possible (paroxetine and linezolid SmPCs, AEMPS). If signs of serotonin syndrome appear, consider stopping one or both drugs (linezolid SmPC, AEMPS). The FDA label says to stop paroxetine and other serotonergic drugs at once and start supportive treatment (paroxetine label, FDA). After a linezolid course, start paroxetine no earlier than 24 hours after the last linezolid dose, with caution and gradual dose increases (paroxetine SmPC, AEMPS). Under the FDA label, wait at least 14 days (paroxetine label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Zyvoxid 2 mg/ml solución para perfusión (linezolid) (2026)– AEMPS, CIMA, nº registro 64106, secciones 4.3 y 4.4
- FDA: Paxil (paroxetine) prescribing information (2026)– Apotex Corp. PAXIL (paroxetine) tablets. Prescribing information, DailyMed setid ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Paroxetina (nº registro 59466), sección 4.3 (2025)– AEMPS, CIMA, nº registro 59466 (Frosinor 20 mg, GlaxoSmithKline), revisión 12/2025, secciones 4.3, 4.4 y 4.5